Back to Agendas
Wednesday Oral Presentations - Professional Poster Session 2B
Session Chair(s)
Julie Ho
Associate Director, Business and Market Development
DIA, United States
New this year! Join us in the Exhibit Hall Poster Area (Hall A Entrance) for a series of 5 minute presentations delivered by this year’s Professional Poster Presenters. View this year’s Professional Poster Program Schedule and Poster Details
The following are scheduled in this session 2B:
- 11:35 - 11:40am W 14 Compliant Presentation of Important Safety Information In A More Educational Format In Promotional Educational Programs
- 11:42 - 11:47amW 15 Strategic Considerations for Developing an Initial Pediatric Study Plan for a Proposed Biosimilar
- 11:49 - 11:54am W 16 A Determination of the Relative Risk of Hepatotoxicity Among Anti-Epileptic Drugs in the FDA Adverse Event Reporting System
- 11:56 am - 12:01pm W 17 Pharmacovigilance Process Innovation: Approach to Pharmacovigilance (PV) Process Enhancements in a Large Global Biotechnology Company
- 12:03 - 12:08 pm W 18 Incidence of Outcomes Relevant to Vaccine Safety Monitoring in a Large Commercially Insured Population
- 12:10 -12:15pm W 19 Global Utilization of Breast Cancer Treatment Guidelines: A Survey of International Physician Practices
- 12:17 - 12:22pm W 20 Precision Medicine Basket Trial Eligibility Across Race/Ethnicity: Implications for Ethnobridging and Clinical Application
- 12:24 - 12:29pm W 21 PMDA’s Relief Services for Drugs’ Adverse Health Effects
- 12:31 - 12:36pm W 23 Recent FDA GLP (Good Laboratory Practice) Inspections Conducted in China
- 12:38 - 12:43pm W 25 Ignoring Global Feasibility and Site Networks for Your Rare Disease Study? You May Want to Re-consider
- 12:45 - 12:50pm W 26 Exploring Phenome-wide Association Study (PheWAS) as an Option to Address Key Challenges of Pharmaceutical Industry
- 12:52 - 12:57pm W 27 Japan PMDA Inspections from a CDM/EDC Perspective
- 12:59 - 1:04pm W 29 Factoring in Ethnicity, Gender, and Age in Specific Clinical Studies
- 1:06 - 1:11pm W 30 Clinical Monitoring Liaison, a New Oversight Role as a Practical Approach to Sponsor Involvement in Outsourced Trials
- 1:13 - 1:18pm W 31 Adaptive Clinical Trial Design in Head-to-Head Comparison of Two DPP-4 Inhibitors
- 1:20 - 1:25 pm W 33 Lessons Learned for Meeting Safety Reporting Requirements in Retrospective Chart Review Studies
Have an account?